NBTX Stock Overview A clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Nanobiotix S.A. Competitors Price History & Performance
Summary of share price highs, lows and changes for Nanobiotix Historical stock prices Current Share Price €2.90 52 Week High €8.96 52 Week Low €2.76 Beta 1.41 1 Month Change 0% 3 Month Change -44.12% 1 Year Change -61.54% 3 Year Change -70.56% 5 Year Change n/a Change since IPO -82.92%
Recent News & Updates
Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth May 24
Nanobiotix S.A. to Report Q1, 2024 Results on May 22, 2024 May 17
Nanobiotix Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating Nbtxr3 for Patients with Stage Three Lung Cancer May 16
Nanobiotix S.A. to Report Q4, 2023 Results on Apr 24, 2024 Apr 19 Nanobiotix S.A. announced that it has received $24.999999 million in funding from Johnson & Johnson Innovation - JJDC, Inc. Dec 05
Nanobiotix S.A. to Report Q3, 2023 Results on Nov 13, 2023 Nov 10 See more updates
Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth May 24
Nanobiotix S.A. to Report Q1, 2024 Results on May 22, 2024 May 17
Nanobiotix Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating Nbtxr3 for Patients with Stage Three Lung Cancer May 16
Nanobiotix S.A. to Report Q4, 2023 Results on Apr 24, 2024 Apr 19 Nanobiotix S.A. announced that it has received $24.999999 million in funding from Johnson & Johnson Innovation - JJDC, Inc. Dec 05
Nanobiotix S.A. to Report Q3, 2023 Results on Nov 13, 2023 Nov 10 Nanobiotix S.A. has completed a Follow-on Equity Offering in the amount of $29.288592 million. Nov 04
Nanobiotix S.A. has filed a Follow-on Equity Offering in the amount of $30 million. Nov 03
Nanobiotix S.A. announced that it expects to receive $25 million in funding from Johnson & Johnson Innovation - JJDC, Inc. Nov 02
Nanobiotix S.A. Announces Updated Preliminary Results from Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis from Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023 Oct 24
Nanobiotix S.A. Announces New Clinical Data from Phase 1 Study Evaluating Radiotherapy-Activated Nbtxr3 for Patients with Pancreatic Ductal Adenocarcinoma Oct 01
Nanobiotix S.A. to Report First Half, 2023 Results on Sep 26, 2023 Sep 20
NANOBIOTIX Announces Expiration of HSR Waiting Period Regarding the Agreement for Worldwide Co-Development and Commercialization of Potential First-in-Class Radioenhancer NBTXR3 Aug 17
Nanobiotix S.A. Announces First Patient Injected in New Phase 1/2 Study Evaluating Radiotherapy-Activated NBTXR3 Plus Anti-PD-1 for Patients With Advanced Cancers Jul 22
Nanobiotix S.A., Annual General Meeting, Jun 27, 2023 May 19
NANOBIOTIX Announces First Patient Randomized in United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer Dec 27
NANOBIOTIX Recommends Phase 2 Dose for NBTXR3 in Pancreatic Cancer Nov 15
NANOBIOTIX Updates Data from its Phase 1 Immunotherapy Study, Study 1100 Nov 10
NANOBIOTIX Announces the Appointment of Global Medical Experts to Scientific Advisory Board Nov 03
Nanobiotix enters final agreement to restructure existing loan with EU's investment bank Oct 18
Nanobiotix GAAP EPS of -€0.76, revenue of €1.33M beats by €0.11M Sep 28
NANOBIOTIX Establishes Recommends Dose for Planned Registrational Study Evaluating NBTXR3 Plus Anti-PD-1 for Patients With Metastatic Head and Neck Cancer Resistant to Prior Immunotherapy Sep 22
Nanobiotix agrees in principle to restructure debt obligations with EU's investment bank Sep 12
Nanobiotix S.A. and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck Cancer Sep 08
French biotech Nanobiotix rebounds to post best ever 47% intraday gain Aug 01
NANOBIOTIX Announces the Reporting of New Data at the 2022 Annual Meeting of the American Society for Clinical Oncology Jun 09
Nanobiotix S.A. Announces the Reporting of New Data At the 2022 Annual Meeting of the American Society for Clinical Oncology Jun 06
Nanobiotix S.A. to Report First Half, 2022 Results on Sep 28, 2022 Jun 03
Nanobiotix S.A. Announces New Data from an Open-Label Preclinical Study Evaluating the Combination of First-in-Class Radioenhancer, NBTXR3, with the Triple Blockade of PD-1, LAG-3, and TIGIT Apr 12
Nanobiotix Announces Publication of New Clinical Case Study Highlighting First Patient Experience of NBTXR3 Treatment for Pancreatic Cancer Feb 10
Nanobiotix S.A. Announces Publication of New Preclinical Immunotherapy Data Showcasing the Combination Potential of NBTXR3 With anti-PD-1 and anti-CTLA-4 Jan 27
Nanobiotix S.A. Announces First Patient Enrolled in NANORAY-312 Global Phase III Registrational Study of NBTXR3 in Head and Neck Cancer Jan 06
Nanobiotix S.A. Announces Red Journal Publication of Preclinical Data Showing Radioenhancer NBTXR3 May 'Reprogram' the Tumor Microenvironment to Overcome Anti-PD-1 Resistance and Evoke Abscopal Effect Oct 01
NANOBIOTIX Announces Initiation of New Clinical Study Evaluating NBTXR3 in Lung Cancer Jul 02
NANOBIOTIX Reports New Data for Potential First-in-Class Radioenhancer NBTXR3 in Combination With Anti-PD-1 Showing Local or Distant Tumor Regression in 76.9% of Evaluable Patients Regardless of Prior Anti-PD-1 Exposure Jun 04
Nanobiotix names Bart Van Rhijn as chief financial officer Jun 01
Nanobiotix Announces Updated Results From Priority Pathways in Head and Neck Cancer and Immunotherapy for Potential First-in-class Radioenhancer NBTXR3 at 2021 Annual Meeting of the American Society for Clinical Oncology May 21
Nanobiotix S.A. Announces New Data from its Oncology Pipeline to Be Present at the 2021 American Society of Clinical Oncology Annual Meeting Apr 29
NANOBIOTIX and PharmaEngine, Inc. Mutually Agree to Conclude Collaboration Mar 05
NANOBIOTIX Announces Positive New Preclinical Data Investigating First-In-Class Radioenhancer NBTXR3 Mar 04 Nanobiotix S.A. to Report Q2, 2021 Results on Sep 03, 2021
Nanobiotix Announces First Patient Injected with NBTXR3 in Esophageal Cancer Jan 29
Nanobiotix Will Disrupt Oncological Radiotherapy Jan 29
NANOBIOTIX Announces Positive First Results for Novel NBTXR3 in Rectal Cancer Study at ASCO-GI 2021 Jan 15 Shareholder Returns NBTX US Biotechs US Market 7D -2.7% -2.3% -2.6% 1Y -61.5% -6.3% 24.5%
See full shareholder returns
Return vs Industry: NBTX underperformed the US Biotechs industry which returned -6.3% over the past year.
Return vs Market: NBTX underperformed the US Market which returned 24.5% over the past year.
Price Volatility Is NBTX's price volatile compared to industry and market? NBTX volatility NBTX Average Weekly Movement 8.5% Biotechs Industry Average Movement 10.8% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.7% 10% least volatile stocks in US Market 3.1%
Stable Share Price: NBTX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: NBTX's weekly volatility (9%) has been stable over the past year.
About the Company Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand.
Show more Nanobiotix S.A. Fundamentals Summary How do Nanobiotix's earnings and revenue compare to its market cap? NBTX fundamental statistics Market cap US$149.45m Earnings (TTM ) -US$34.35m Revenue (TTM ) US$43.31m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) NBTX income statement (TTM ) Revenue €42.20m Cost of Revenue €0 Gross Profit €42.20m Other Expenses €75.68m Earnings -€33.47m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -0.71 Gross Margin 100.00% Net Profit Margin -79.31% Debt/Equity Ratio -204.3%
How did NBTX perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/02 23:42 End of Day Share Price 2025/01/02 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Nanobiotix S.A. is covered by 14 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Mickael Chane-Du Bryan Garnier & Co Philippa Gardner Edison Investment Research Jonathan Miller Evercore ISI
Show 11 more analysts 
